• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉扎贝胺(一种可逆性单胺氧化酶B选择性抑制剂)的线性与非线性混合处置

Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

作者信息

Guentert T W, Holford N H, Pfefen J P, Dingemanse J

机构信息

Department of Clinical Pharmacology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

出版信息

Br J Clin Pharmacol. 1994 Jun;37(6):545-51. doi: 10.1111/j.1365-2125.1994.tb04302.x.

DOI:10.1111/j.1365-2125.1994.tb04302.x
PMID:7917772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1364813/
Abstract
  1. Single oral doses (100-300 mg) and multiple oral doses (100-350 mg 12 hourly for 7 days) of lazabemide were administered to 35 young and 40 elderly healthy subjects. Plasma concentrations of unchanged drug were determined to study the dose-concentration relationship. 2. The elimination phase time course of lazabemide concentrations indicated concentration-dependent elimination after both single and multiple dosing. Nevertheless, maximum concentrations and areas under concentration-time curves increased almost proportionally with dose and accumulation after chronic dosing was less than a factor of 2; steady-state concentrations were achieved by the third day of dosing. The apparent half-life determining accumulation was approximately 8-9 h. 3. Drug absorption commenced rapidly after a dose; two components to the absorption process were detectable in young subjects possibly due to simultaneous administration of multiple tablets at the higher doses. 4. Observations after single and multiple dosing were described with a compartmental model allowing for parallel saturable (population mean +/- s.d.: maximum elimination rate Vmax/F: 2.8 +/- 1.4 mg h-1; concentration at half-maximum elimination Km: 36 +/- 19 micrograms l-1) and first-order (CL/F 16 +/- 3.8 l h-1) elimination pathways. No important difference between the young and the elderly subjects was noted in absorption or disposition parameters of lazabemide.
摘要
  1. 对35名年轻和40名老年健康受试者给予单次口服剂量(100 - 300毫克)和多次口服剂量(100 - 350毫克,每12小时一次,共7天)的拉扎贝胺。测定未变化药物的血浆浓度以研究剂量 - 浓度关系。2. 拉扎贝胺浓度的消除相时程表明,单次和多次给药后均存在浓度依赖性消除。然而,最大浓度和浓度 - 时间曲线下面积几乎与剂量成比例增加,慢性给药后的蓄积小于2倍;给药第三天达到稳态浓度。决定蓄积的表观半衰期约为8 - 9小时。3. 给药后药物吸收迅速开始;在年轻受试者中可检测到吸收过程的两个成分,可能是由于较高剂量时同时服用多片药物所致。4. 用一个房室模型描述单次和多次给药后的观察结果,该模型允许平行的可饱和(总体均值±标准差:最大消除速率Vmax/F:2.8±1.4毫克/小时;消除半最大浓度Km:36±19微克/升)和一级(CL/F 16±3.8升/小时)消除途径。在拉扎贝胺的吸收或处置参数方面,年轻和老年受试者之间未发现重要差异。

相似文献

1
Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.拉扎贝胺(一种可逆性单胺氧化酶B选择性抑制剂)的线性与非线性混合处置
Br J Clin Pharmacol. 1994 Jun;37(6):545-51. doi: 10.1111/j.1365-2125.1994.tb04302.x.
2
Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.单剂量和多剂量单胺氧化酶-B抑制剂拉扎贝胺在健康受试者体内的药代动力学和药效学
Br J Clin Pharmacol. 1997 Jan;43(1):41-7.
3
Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.拉扎贝胺的药效学,一种单胺氧化酶B的可逆性和选择性抑制剂。
Br J Clin Pharmacol. 1994 Jun;37(6):553-7. doi: 10.1111/j.1365-2125.1994.tb04303.x.
4
Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.拉扎贝胺对早期帕金森病残疾进展的影响。帕金森研究小组。
Ann Neurol. 1996 Jul;40(1):99-107. doi: 10.1002/ana.410400116.
5
Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.在联用拉扎贝胺和吗氯贝胺期间的酪胺药效学。
Int J Clin Pharmacol Ther. 1996 Apr;34(4):172-7.
6
Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.
Clin Pharmacol Ther. 1987 Oct;42(4):395-404. doi: 10.1038/clpt.1987.169.
7
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.l-多巴-拉扎贝胺前药的设计与评价用于治疗帕金森病。
Molecules. 2017 Nov 27;22(12):2076. doi: 10.3390/molecules22122076.
8
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.利拉利汀,一种开发用于治疗 2 型糖尿病的二肽基肽酶-4 抑制剂:在健康成年日本男性受试者中进行的单次和多次递增剂量、随机、双盲、安慰剂对照的 I 期临床试验。
Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.
9
A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.司来吉兰的新剂型:提高生物利用度及对单胺氧化酶B抑制的选择性。
J Neural Transm (Vienna). 2003 Nov;110(11):1241-55. doi: 10.1007/s00702-003-0036-4.
10
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.沙芬酰胺的药代动力学和药效学,一种具有抗帕金森病和抗惊厥活性的神经保护剂。
Pharmacol Res. 2004 Jul;50(1):77-85. doi: 10.1016/j.phrs.2003.12.004.

引用本文的文献

1
Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.拉扎贝胺的药效学,一种单胺氧化酶B的可逆性和选择性抑制剂。
Br J Clin Pharmacol. 1994 Jun;37(6):553-7. doi: 10.1111/j.1365-2125.1994.tb04303.x.

本文引用的文献

1
Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.拉扎贝胺的药效学,一种单胺氧化酶B的可逆性和选择性抑制剂。
Br J Clin Pharmacol. 1994 Jun;37(6):553-7. doi: 10.1111/j.1365-2125.1994.tb04303.x.
2
A Bayesian approach to nonlinear random effects models.非线性随机效应模型的贝叶斯方法。
Biometrics. 1985 Dec;41(4):1015-23.
3
Clinical pharmacology of monoamine oxidase inhibitors.单胺氧化酶抑制剂的临床药理学
Clin Neuropharmacol. 1986;9(3):207-34. doi: 10.1097/00002826-198606000-00001.
4
Clinical pharmacokinetics of ethanol.乙醇的临床药代动力学
Clin Pharmacokinet. 1987 Nov;13(5):273-92. doi: 10.2165/00003088-198713050-00001.
5
Commentary: a physiological approach to hepatic drug clearance.述评:肝脏药物清除的生理学方法
Clin Pharmacol Ther. 1975 Oct;18(4):377-90. doi: 10.1002/cpt1975184377.